Mayo Clinic researchers have identified new scoring criteria allowing for the detection of treatable forms of rapidly progressive dementia (RPD) with reasonably high confidence during a patient’s first clinical visit. This scoring criteria may allow physicians to substantially reduce the time it takes to begin treatment. The findings are published in the Annals of Neurology.
Recent Posts
- CAR NK cell therapy clinical trial puts follicular lymphoma survivor into remission
 - Stem cell therapy linked to lower risk of heart failure after a heart attack
 - Embryo-Like ‘Blood Factories’ Could One Day Supplement Donations
 - Long-Term Growth Hormone Therapy Boosts Pediatric Stem Cells
 - New UCLA drug could restore heart and organ function
 - Parkinson’s treatment tested at UW showing promise in first clinical trial
 
				
												

